Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423183 | 1.00 | CASP3 (0.51) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL29443002 | 1.00 | CASP3 (0.51) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL4581609 | 1.00 | CASP3 (0.51) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL8950475 | 0.90 | CASP3 (0.60) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL4468251 | 0.90 | CASP3 (0.60) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL4476083 | 0.90 | CASP3 (0.60) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL8668395 | 0.86 | CASP3 (0.41) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL8668397 | 0.86 | CASP3 (0.41) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL7525034 | 0.85 | CASP3 (0.49) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL21901972 | 0.82 | CASP3 (0.53) | CASP3CA12CA9GLSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BOLT BIOTHERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4463450-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | Bisichem Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240294876-A1 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIV SOUTHERN CALIFORNIA (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024137619-A1 | ANTI-CLAUDIN, BIS-BENZIMID AZOLE STING AGONIST IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4341386-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | University of Southern California (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117751182-A | Method for amplifying human granulocyte-macrophage progenitor cells and application thereof | 南加利福尼亚大学 | 2024-03-22 | — | — | CN | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
| WO-1993016073-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
| WO-1993014112-A1 | SUBSTITUTED PHOSPHINIC ACID-CONTAINING PEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1993-07-22 | — | — | WO | disclosed |
| EP-0472181-A2 | 5-Amine substituted adenosine analogs as immunosuppressants | MERRELL PHARMACEUTICALS INC. (US) | 1992-02-26 | — | — | EP | disclosed |
| EP-0210782-B1 | PYRIDINE COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1991-04-17 | — | — | EP | disclosed |
| EP-0358536-A2 | Novel S-adenosyl methionine decarboxylase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1990-03-14 | — | — | EP | disclosed |
| EP-0351475-A1 | S-Adenosylmethionine decarboxylase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-01-24 | — | — | EP | disclosed |
| US-4778796-A | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1988-10-18 | — | — | US | disclosed |
| EP-0210782-A2 | Pyridine compounds, process for the preparation thereof and pharmaceutical composition containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-02-04 | — | — | EP | disclosed |
| EP-0178503-A1 | Butenyl derivatives, process for their preparation and medicines containing them | LUDWIG HEUMANN & CO GMBH (DE) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | CASP3 2722/4885CA12 3520/4885CA9 3149/4885 |
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | IDO2, IDO1, BCR | CASP3 848/4885CA12 453/4885CA9 968/4885 |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | STING1, PDCD1LG2, CD274 | CASP3 2004/4885CA12 3397/4885CA9 3359/4885 |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCR2, CXCR1 | CASP3 2144/4885CA12 2293/4885CA9 3659/4885 |
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BCL6, CLTB, MET | CASP3 2019/4885CA12 684/4885CA9 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.